ArticleAntimicrobial agents and chemotherapy2018
Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- 4-Hydroxy-3-Methyl-2-Alkenylquinoline Disrupts Temporospatial Control of Flagellar Assembly and Induces Transcriptomic Remodeling inMolecules (Basel, Switzerland) · 2026Article
- Article
- Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment forAntibiotics (Basel, Switzerland) · 2023Review
- Selective Bacteriocins: A Promising Treatment forAntibiotics (Basel, Switzerland) · 2023Article
- Mechanism of Action of Ribosomally Synthesized and Post-Translationally Modified Peptides.Chemical reviews · 2022Review
- Efficiency of Antimicrobial Peptides Against Multidrug-Resistant Staphylococcal Pathogens.Frontiers in microbiology · 2022Review
- Evaluation of analogs of mutacin 1140 in systemic and cutaneous methicillin-resistantFrontiers in microbiology · 2022Article
- Substrate Sequence Controls Regioselectivity of Lanthionine Formation by ProcM.Journal of the American Chemical Society · 2021Article
- Article
- Antimicrobial Peptides with Antibacterial Activity against Vancomycin-ResistantInternational journal of molecular sciences · 2021Review
- Therapeutic Application of Lantibiotics and Other Lanthipeptides: Old and New Findings.Applied and environmental microbiology · 2021Review
- Toward understanding the signals of bacteriocin production by Streptococcus spp. and their importance in current applications.World journal of microbiology & biotechnology · 2021Review
- Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mutacin 1140, a member of the epidermin family of type AI lantibiotics, has a broad spectrum of activity against Gram-positive bacteria. It blocks cell wall synthesis by binding to lipid II. Although it has rapid bactericidal effects and potent activity against Gram-positive pathogens, its rapid clearance and short half-life
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.